Johnson & Johnson’s IMAAVY (nipocalimab-aahu) has received FDA approval as the first treatment specifically for warm autoimmune hemolytic anemia (wAIHA) in adults and in patients 12 years and older who are corticosteroid-treated or previously treated.

The August 2026 FDA decision expands IMAAVY’s labeled population to include patients aged 12 and up with wAIHA, marking a rare-disease milestone for J&J.

IMAAVY is an FcRn blocker that reduces pathogenic IgG autoantibodies while aiming to preserve B-cell function, with trial data showing a meaningful hemoglobin response in a significant subset of patients.

Analysts project potential peak annual revenue of at least $5 billion across indications if multi‑year adoption and additional indications materialize.

Investors should weigh ongoing talc litigation risk and related cash-flow implications despite the positive regulatory result.

Pricing decisions, payer coverage, and ENERGY trial results will continue to shape access and adoption as more data emerges.

Imaavy sits within J&J’s immunology portfolio, which is supported by other products and a broader pipeline including potential launches and ongoing programs.

Johnson & Johnson reorganized into two main divisions—medical technology and pharmaceuticals—after spinning off its consumer health business in 2023.

Trial outcomes indicate that about a quarter of treated patients met the primary endpoint, signaling a meaningful but not universal benefit and positioning IMAAVY as a new option rather than a cure.

The company maintains a generous dividend streak, with ongoing shareholder returns supported by a large cash position despite debt and liabilities.

IMAAVY is administered intravenously at a dosing of 30 mg/kg every four weeks; pregnancies require clinician discussion due to unknown fetal/infant effects.

The trial and commentary include potential conflicts of interest, as some researchers and the sponsoring company have prior or ongoing consultancies.